If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

The purpose of this study is to compare diet (record of the foods you eat), gut microbiome (stool sample), and cells (blood sample) in adults with IgA Nephropathy (IgAN) and compare with adults with focal segmental glomerulosclerosis (FSGS) and adults with no history of medical problems. The information we learn by doing this study may help us understand how we might be able to target the microbiome to better understand the disease process and potentially help us develop new therapies in the future.

Patients hospitalized with anti-glomerular basement membrane (anti-GBM) antibody disease, an autoimmune disease, are treated with a number of medications to stop the inflammation created by the disease. In this study, we want to see if adding the drug imlidifase to those usual treatments will stop the inflammation faster and helps reduce damage to the kidneys.

People with kidney disease that have the APOL1 risk variant are at a greater risk for developing protein in their urine and chronic kidney disease. This research study is being done to determine if the investigational drug, VX-147 can slow or stop the worsening of kidney function as well as target the underlying cause of kidney disease.

The purpose of this study is to test a medication called voclosporin in adolescent lupus nephritis patients. Voclosporin is approved for use in adult patients with active lupus nephritis but not for children or adolescents.

This study is trying to learn more about a medication called sparsentan, and how it can help the kidneys filter protein and slow the decline of kidney function. The amount of protein found in the urine (called proteinuria) is seen as a marker of kidney function. Lowering proteinuria levels is associated with better kidney health outcomes.

We still have a lot to learn about why people develop glomerular disease and what the best medicines are to treat these diseases. Diabetes is a common, chronic illness and many people with glomerular disease also have diabetes. Currently, there is no information telling us the best ways to treat patients with both diabetes and glomerular disease, or how to counsel them about prognosis and risks for complications. This substudy of the Cure Glomerulopathy Network brings together information and laboratory specimens from patients with diabetes and glomerular disease to speed up and improve health research for their care.

If you are seen at UNC and have been diagnosed with monoclonal gammopathies or amyloidosis, and the disease is affecting your kidneys, we would like your permission to access your medical record to learn about your treatments and how well they work.

This is a three-year research study for people with primary membranous nephropathy (primary MN). The study will test if combining belimumab and rituximab is effective in treating Primary MN.

To evaluate the safety and efficacy of a device removing lipids from the blood using an apheresis device in treating primary FSGS